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Abstract
Background: Several lines of evidence suggest that transcription factors are involved in the pathogenesis of Multiple
Sclerosis (MS) but complete mapping of the whole network has been elusive. One of the reasons is that there are several
clinical subtypes of MS and transcription factors that may be involved in one subtype may not be in others. We investigate
the possibility that this network could be mapped using microarray technologies and contemporary bioinformatics
methods on a dataset derived from whole blood in 99 untreated MS patients (36 Relapse Remitting MS, 43 Primary
Progressive MS, and 20 Secondary Progressive MS) and 45 age-matched healthy controls.
Methodology/Principal Findings: We have used two different analytical methodologies: a non-standard differential
expression analysis and a differential co-expression analysis, which have converged on a significant number of regulatory
motifs that are statistically overrepresented in genes that are either differentially expressed (or differentially co-expressed) in
cases and controls (e.g., V$KROX_Q6, p-value ,3.31E-6; V$CREBP1_Q2, p-value ,9.93E-6, V$YY1_02, p-value ,1.65E-5).
Conclusions/Significance: Our analysis uncovered a network of transcription factors that potentially dysregulate several
genes in MS or one or more of its disease subtypes. The most significant transcription factor motifs were for the Early
Growth Response EGR/KROX family, ATF2, YY1 (Yin and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodimers, SOX5, and CREB
and ATF families. These transcription factors are involved in early T-lymphocyte specification and commitment as well as in
oligodendrocyte dedifferentiation and development, both pathways that have significant biological plausibility in MS
causation.
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Introduction
Multiple Sclerosis (MS) [1] is an autoimmune disease char-
acterised by chronic inflammatory demyelination of the central
nervous system. The disorder affects millions of people worldwide
and is the most common chronic disease of the central nervous
system that begins in early to middle adult life [2] (its prevalence in
the USA is 0.9 per 1,000 [3]). MS is a multifactorial and
heterogeneous disease, and although its causes are currently
unknown it is increasingly clear that both genetic and environ-
mental factors contribute to susceptibility [2,4–6]. Evidence for
genetic risk includes familial aggregation [5,7] and differences in
prevalence between ethnic groups [8–10] (caucasians of Northern
European ancestries appear to be particularly susceptible). It is
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14176now well established that certain genes influence susceptibility to
MS – human leukocyte antigen HLA DRB1*1501 [11], IL2RA,
IL7R, CLEC16A [12–16], and others [17–23].
There are three principal clinical subtypes of MS, the most
prevalent being: relapsing remitting (RRMS), where unpredictable
relapsing episodes alternate with periods of remission; primary
progressive (PPMS), where there is steady progression of the illness
from onset; and secondary progressive (SPMS), where after an
initial relapsing remitting pattern, there is progressive neurological
decline with or without relapses. The question of whether some
MS subtypes are associated with particular susceptibility genes is
open and merits further examination. Currently there is only
modest evidence for any association [24,25], and these have been
challenged [26].
Previous research has demonstrated the potential of differential
gene expression profiling in elucidating complex traits, including
disease susceptibility, when expression is measured in tissue related
to the trait under study [27]. A companion study [28] to the work
presented here applied traditional statistical analysis to whole
blood mRNA transcriptome of all known genes in a gene
expression study of MS. The results were combined with results
from the genome-wide association study published by the
ANZgene GWAS[21]. The expression of 48,000 gene probe
sequences in human HT-12 beadarray chips (Illumina Inc., CA,
USA) hybridized with cDNA from 99 untreated MS patients (36
RRMS, 43 PPMS, and 20 SPMS) and 45 age-matched healthy
controls, identifying over 19,000 gene probes expressed in the
blood cells with a large number that were differentially expressed
between the controls and MS sample groups. Functional profiling
of the differentially expressed genes revealed that the cells in whole
blood are more active in MS, being engaged in translation and
energy production through oxidative phosphorylation to a greater
extent. Additionally, T cells accounted for the greatest percentage
of differentially expressed (in controls versus MS collectively)
immune cell ‘‘tagging’’ genes. Together, these results are consis-
tent with the prevailing view that autoreactive T cells play a key
role in the pathogenesis of MS.
Evidence suggests that transcription factors are involved in the
pathogenesis of MS and other autoimmune diseases [29,30]. For
example, it has previously been observed that members of the NF-
kappaB, STAT, AP-1 and E2F families [30–56], IRF-1
[36,46,47,57], IRF-2 [58], IRF-5 [59], IRF-8 [20], CREB
[36,46], PPARgamma and PPARalpha [60–68], SP1 [59], SP3
[69–71], RORC [72], NR4A2, TCF2 [73], ETS-1 [74] and
FOXP3 [75–85] may be implicated in MS and its disease
subtypes. This paper aims to complement the companion study by
uncovering, thanks to combinatorial optimization and differential
co-expression methods and a different focus in the analysis,
transcription factors that potentially dysregulate many genes in
MS. The working hypothesis is that, given consistent sets of genes
exhibiting differential expression or co-expression patterns be-
tween two classes, this change is attributed to a set of transcription
factors. Ultimately, our goal is to piece together relationships and
infer a network of transcription factors that are implicated in MS
and its subtypes as inferred from the differential expression and co-
expression of several hundreds of genes.
We are aware that a cautionary note is required to our study and
all others that aim to correlate variations in the transcriptome of
whole-blood with gene expression and its regulation mechanisms
and their consequences in the brain (for instance, those of
oligodendrocyte de-differentiation). There exist few studies in the
area. In a recent study [86], the consistency between expression
patterns between brain and blood was analysed. Although important
differences were observed (around 90% of all transcripts examined
presented variations in the alternative splicing index in brain and
blood), a large number of brain transcripts (4,100) co-expressed in
blood samples. This means, on the biomarker identification phase,
that they can be further explored in experimental studies of either
blood or cell lines from patients with MS.
As the effects of processing whole blood may also contribute to
changes of these gene expression patterns, our cautionary note
remains until we could better narrow the valid consistencies. In
some sense, the diagnostic need of a simple blood test for MS, as
well as our present atlas of expression changes with this technology
will certainly motivate useful studies like the one in [86] to bridge
this gap.
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus [87], and are accessible
through GEO Series accession number GSE17048 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17408).
Results
Two different analyses were used to define potentially relevant
transcription factors. Gene expression using microarray detection
techniques utilize short sequences (‘‘probes’’) that target specific
genes, and even specific protein isoforms (particularly true in
Illumina technology). All differential expression or co-expression
analysis here are performed on individual probe identifiers, while
transcription factor overrepresentation are performed based on the
target genes identifiers. The first identified gene probes differen-
tially expressed between the four different clinical groups in the
study’s sample set; the second, groups of gene probes pair-wise
differentially co-expressed between control and MS samples. The
first analysis is better at revealing differences in gene expression
between the sample groups, while the second aims to find specific
groups of genes which have lost their normal pattern of co-
expression and are affected by MS irrespective of disease subtype.
Overrepresented binding motifs, and their corresponding tran-
scription factors, were obtained for the groups of genes identified
under both approaches.
Seven molecular genetic signatures were derived from the whole
blood mRNA expression data collected in [28] (our companion
study) and then profiled for overrepresented TRANSFAC motifs.
Each signature contained a set of gene probe sequences that are
differentially expressed between a pair of sample groups specified by
the signature’s denotation (C/MS, C/PP, C/RR, C/SP, PP/RR,
RR/SP, or PP/SP); for example, C/PP contained genes differen-
tially expressed between control and PPMS samples. The signatures
were obtained using a three-step filtering process that discards the
probes that are least relevant for distinguishing between the pair of
sample groups according to formal criteria: Standard detection p-
value initial filtering, then an entropy-based selection procedure
[88], and finally, an (a,b)-k-feature set selection method [89,90],
which removes probes based on statistical significance, information
content, and predictive ability respectively. More details are
provided in the Materials and Methods section. This methodology
has been used to identify robust gene sets associated to a variety of
diseases, including Alzheimer’s [89,91], Parkinson’s [92], and
prostate cancer [93]. Gene sets obtained by this methodology
maximise intra-class coherency and inter-class discriminatory
power with the minimum number of genes[94].
Figures 1–7 depict the signatures and their corresponding
clustered heatmaps, while detailed listings are provided in
supporting information Table S1, Table S2 and Table S3, with
combined summary, listing and overlap with the companion study
signatures in supporting information Table S4. We note that the
heatmap for C/MS (Figure 1) exhibits a lack of coherence in the
MS Transcription Factor Map
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the MS group as a whole. Coherence increases when the MS
subtypes are considered separately (C/PP: Figure 2, C/RR:
Figure 3, C/SP: Figure 4, PP/SP: Figure 5, PP/RR: Figure 6, and
RR/SP: Figure 7), suggesting a correlation between disease
subtype and gene expression. The heatmaps containing SPMS
samples (Figures 4, 5, and 7) are less coherent overall than those
for PPMS (Figures 2, 5, and 6) and RRMS (Figures 3, 6, and 7),
suggesting that SPMS is the most heterogeneous MS subtype with
respect to gene expression in our study. A noticeable pattern of
‘‘bars’’ does appear in the PPMS samples in C/PP (Figure 2),
though, which could be evidence of distinct PPMS subtypes with
contrasting gene expression for the genes in the bars.
Analysis of Differential Gene Expression
A profile of overrepresented regulatory sequences was obtained
for each of the seven signatures using the profiling tool GATHER
[95] (See supporting information Table S5). The profiles contain
Figure 1. mRNA expression heatmap for the C/MS signature. Samples are placed along the horizontal axis and mRNA probe sequences along
the vertical axis. Samples are colour-coded in the bottom horizontal bar (controls: blue; MS: green, as RR: red, SP: yellow, PP: grey). Clustering witha
high-performance memetic algorithm (described in [285]) has ordered the samples and probe sequences, revealing four quadrants that are primarily
up- (red) or down- (green) regulated. Note that division into up/down regulated is more coherent in the control samples than the MS samples.
doi:10.1371/journal.pone.0014176.g001
MS Transcription Factor Map
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the genes for each signature, which appear overrepresented with p-
value ,0.05. The complete profiles for all signatures are given in
Figure 8. Inspection of the profiles reveals that, with the exception
of C/RR and C/SP, there is only a modest intersection between
any pair of profiles. In contrast, nearly half of the motifs in each of
the C/RR and C/SP TRANSFAC profiles (six motifs) occur in
the intersection of the pair. The C/RR and C/SP signatures share
only 12 gene probes (the signatures contain 267 and 113 probes
respectively), which is not enough to account for the amount of
agreement between their TRANSFAC profiles. In fact, the
composition of the TRANSFAC profiles was unchanged when
the 12 probes were removed from C/RR and C/SP and the
profiles recomputed. These observations suggest that any path-
ways of transcriptional dysregulation occurring in MS are likely to
be largely distinct in the PPMS subtype, while overlapping
considerably in RRMS and SPMS. (We note a similar finding in
the companion study [28] using a different methodology: RRMS
and SPMS share more dysregulated gene ontology pathways –
principally immune regulation pathways– with each other than
with PPMS.)
Additionally, we profiled the above TRANSFAC profiles
themselves to reveal higher-level overrepresented regulatory
sequences. These higher-level regulatory sequences – which
effectively identify ‘regulators of regulators’ – were obtained by
TRANSFAC profiling the coding genes of transcription factors
corresponding to key sequences in the above TRANSFAC profiles.
We considered the identification of the key sequences to be a
problem of combinatorial optimization (specifically, a generaliza-
tion of the Hitting Set problem) as described under Materials and
Methods. The resulting higher-level sequences are given in Figure 8
(HS column) and Table 1.
Binding Motifs for KROX/EGR Family, ATF2, and YY1
are Significantly Overrepresented in MS Subtypes. We
highlight the appearance of V$E2F1DP1_01 complex (p-value
,4.28E-5), V$DEAF1_01 (p-value ,4.28E-5), V$MAZR_01 (p-
value ,1.0E-3) and V$E2F4DP2_01 (p-value ,1.1E-3).
V$DEAF1_01 is a binding motif for the DEAF1 (deformed
epidermal autoregulatory factor 1 homolog/NUDR/Supressin)
transcriptionfactor,whichhas been relatedtonegativeregulationof
T-lymphocytes [96], and recently linked to altered tissue-specific
antigen expression in the lymphoid system and autoimmune
diabetes [97,98].
Finally, we profiled up-/down regulated subsets of the signatures
to reveal any regulatory sequences associated with increased/
decreased expression only. The intersection of the signatures is
depicted in Figure 9, while Figure 10 shows the complete profiles for
eachsignaturesubset.Wenote the transcriptionfactormotifsforthe
KROX/EGR family (V$KROX_Q6, p-Value ,3.31E-6), for
ATF2 (V$CREBP1_Q2, p-Value ,1.0E-5) and for YY1
(V$YY1_02, p-Value ,1.65E-5) as the most significantly overrep-
resented (see Table 2, second block).
Remarks on the presence of some probes in the genetic
signature that discriminates Controls from MS
patients. The heterogeneity of the C/MS signature makes it
relatively difficult to talk about individual probes, as it is unlikely
that they will have the same pattern of expression across all
subtypes of MS. Nevertheless, we highlight the following for future
discussion. First, a probe for LOC649143 (similar to HLA class II
histocompatibility antigen, DRB1-9 beta chain precursor (MHC
class I antigen DRB1*9) (DR-9) (DR9)) has a tendency to be
consistently upregulated in controls but not in MS samples.
Second, a probe for LOC650557 (similar to HLA class II
histocompatibility antigen, DQ(W1.1) beta chain precursor
(DQB1*0501)) has the opposite behaviour, a tendency to be
downregulated in controls. CASP8 (caspase 8, apoptosis-related
cysteine peptidase) appears upregulated in MS and RRMS groups;
the protective effect of its inhibition to oligodendrocytes has been
suggested in [99]. Finally, several MS samples have higher
expression for a probe of KIR2DS5 (Homo sapiens killer cell
immunoglobulin-like receptor) [100,101] than in controls
(KIR2DS5 was also part of a study of KIRs in [102]).
Remarks on the presence of some probes in the genetic
signature that discriminates Controls from PPMS
patients. FOXO3 [103–106] is downregulated in many of the
PPMS samples. Deficiency in FOXO3 leads to spontaneous
lymphoproliferation, associated with inflammation of several
organs, in the absence of overt apoptotic defects [107]. FOXO3
regulates, by inhibiting NF-kappaB activity [108], the tolerance
and activation of T cells and is proposed as an inhibitor of
inflammatory transcriptional activity [107].
An interesting finding in this signature is the presence of a probe
for HAR1A (highly accelerated region 1A (non-protein coding)).
HAR1A was first identified in 2006 by Katherine Pollard et al. as
part of a novel ‘‘RNA gene’’ expressed specifically in Cajal-Retzius
neurons in the developing human neocortex from 7 to 19 weeks of
gestation [109] and co-expressed with reelin (which is an
extracelluar matrix protein that is considered essential in the
laminar organization of structures in the brain during develop-
ment). Panteri et al. have reported that reelin is secreted by
Schwann cells in the developing peripheral nerve, is dowregulated
in adult stages, and induced following sciatic never injury. They
have proposed reelin as a factor in determining the final calibre of
myelinated axons and the absolute number of fibers per unit area
in the peripheral nervous system [110]. What makes HAR1A
somewhat unique is that it is one of the ‘‘highly accelerated
regions’’ [111], where evolutionary mechanisms have created
pressure for the emergence of ‘‘human-specific’’ brain features.
HAR1A has been found by whole genome bioinformatics
comparisons and is at centre stage of research on the functional
genomic implications of these new non-coding RNA structures
[109,112]. In the present study, HAR1A is one of two highly
accelerated regions that we point to as interesting putative
biomarkers; the other is in a protein-coding region and is discussed
later. We highlight, however, the presence of SNHG5 (small
nucleolar RNA host gene 5 (non-protein coding)), located on
chromosome 6q15 [113,114], in this signature. Both non-protein-
coding probes warrant further investigation into the role that they
may have in neurological diseases, especially MS.
Other notable biomarkers include CD52, RNASE2, and EGR3
(upregulated in PPMS in comparison to Controls). The CD52
molecule (Cambridge pathology 1 antigen, CAMPATH-1 antigen)
[115–123] is targeted by Alemtuzumab and there are recent
reports that indicate that it may be an effective treatment for early
MS [124]. RNASE2 (ribonuclease, RNase A family, 2 (liver,
eosinophil-derived neurotoxin)) [125,126] is linked to selective
neuronal and axonal damage to white matter of cerebellum and
spinal cord of experimental animals when injected intrathecally
Figure 2. mRNA expression heatmap for the C/PP signature. Control samples (blue), PPMS (grey). Note the pattern of ‘bars’ near the bottom
right of the heatmap (circled) where expression broadly alternates between up- (red) and down- (green) regulated in disease. This regular pattern
could indicate that PPMS contains distinct subgroups with respect to gene expression.
doi:10.1371/journal.pone.0014176.g002
MS Transcription Factor Map
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has apparently never been previously reported – neither in PPMS
nor in other clinically defined subtypes of MS – and thus could be
an important finding. EGR3 is a member of the KROX/EGR
family of genes that code for immediate-early transcription factors
[128,129], which regulate thymocyte proliferation during the
transition from CD42CD82 to CD4+CD8+ [130], and with
EGR2 is a negative regulator of T-cell activation [131] and
development (see [132–134]). Experiments in mice show that
together with EGR1/KROX-24 and SOX10, it cooperates to
activate the Myelin Protein Zero (Mpz) intron element by EGR2
[135]. A common pathway for developmental regulation of Mpz
and other peripheral myelin genes has been proposed [135].
EGR3 was also linked to myelination in Schwann cells, hence
dysregulation of these concerted pathways may have consequences
for neuropathies [136].
Remarks on the presence of some probes in the genetic
signature that discriminates Controls from RRMS
patients. We again note the presence of a probe for
LOC649143 (similar to HLA class II histocompatibility antigen,
DRB1-9 beta chain precursor (MHC class I antigen DRB1*9)
(DR-9) (DR9)). Another probe that seems to be consistently
upregulated in controls but not in MS samples is for HLA-DQB1
(major histocompatibility complex, class II, DQ beta 1). This is of
potential interest in view of the strong evidence that the expression
of the MHC class II Allele HLA-DRB1*1501 is regulated by
vitamin D [137]. The analysis involved sequencing the vitamin D
response element (VDRE) in more than 1,000 chromosomes from
HLA-DRB1 homozygotes; they localised a single MHC (VDRE)
to the promoter region of HLA-DRB1, while there was an
important variation in non-MS-associated haplotypes [137]. We
also observe a number of upregulated ribosomal protein genes
(including RPS10, RPS14, RPL12, RPL24, etc) in this signature.
With a different behaviour, we should cite a probe for VDR
(Vitamin D (1,25- dihydroxyvitamin D3) receptor) and, as in the
C/MS signature, a probe for LOC650557 (HLA class II
histocompatibility antigen, DQ(W1.1) beta chain precursor
(DQB1*0501)), which are upregulated in MS. Other interesting
biomarkers include CA2 (Carbonic anhydrase II) (downregulated
in RRMS), IRF5 (Interferon Regulatory Factor 5) and CD3D
(CD3d molecule, delta (CD3-T-cell receptor complex)), both
upregulated in RRMS. CA2 is localized to oligodendrocytes,
myelin, and choroid plexus epithelium in the human brain [138].
In 1996, Cammer reported delays on oligodendorcyte maturation
in mutant mice deficient in CA2 [139,140].
IRF5, SOD1, NF1 (neurofibromin 1), CD3D, ADAM-17
(ADAM metallopeptidase domain 17) and ILF2/NF45 (interleukin
enhancer binding factor 2, 45 kDa), on the contrary, have a
tendency to be upregulated in RRMS samples. An allele in IRF5
has been reported as conferring an increased risk for inflammatory
bowel diseases, systemic lupus erythematosus and MS, suggesting
that there is a link between IRF5 and several autoimmune diseases
[59,141]. SOD1 and NF1 and their homologues have appeared in
our gene ontology search as linked with several types of
myelopathies and familial amyotrophic lateral sclerosis [142–
151]. NF1 is expressed in cortical neurons and oligodendrocytes
and sensory neurons and Schwann cells in the peripheral nervous
system [152–154]. There are anecdotal clinical reports of
neurofibromatosis type 1 and MS co-ocurring in patients
[155,156]. OMgp, the oligodendrocyte-Myelin glycoprotein gene,
Figure 3. mRNA expression heatmap for the C/RR signature.
Control samples (blue), RRMS (red).
doi:10.1371/journal.pone.0014176.g003
MS Transcription Factor Map
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doi:10.1371/journal.pone.0014176.g004
MS Transcription Factor Map
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upregulated in RRMS samples and is involved in TCR activation
[158] and T-cell development [159–161]. ADAM-17 has been
observed to be upregulated in MS lesions in brain tissue [162].
Viral Pathways are Significantly Overrepresented in the
genetic signature that discriminates between Controls and
PPMS patients. Each signature was also functionally profiled
using g:PROFILER [163], which integrates several profiling
resources, including Gene Ontology, KEGG and Reactome
pathways, and TRANSFAC sequence motifs. Only three of the
signatures, C/MS, C/RR, and C/PP, had profiles containing
significant terms. However, g:PROFILER’s significance test is
considered to be very conservative, so profiles derived under a less
stringent significance criterion, p-value ,0.005, are provided
(supporting information Table S6).
There is a group of nine ribosomal genes (RPL27, RPL35,
RPL35A, RPL39, RPS5, RPS14, RPS15A, RPS27A, and
RPLP0P2) in the C/PP signature that are responsible for almost
all the terms in its profile (see Table S6). Most of these terms relate
to influenza or translation Reactome pathways – principally
translation initiation, translation elongation and influenza viral
RNA transcription and replication. Although influenza itself is
considered unlikely to be involved in MS, other viruses have been
linked to autoimmune diseases. One viral theory of MS relates
genetic sequences for viruses to similar sequences that code for the
myelin sheath [164]. T cells adapted for the protein products of
the virus sequence could mistakenly recognize myelin proteins as
antigens and, were they to penetrate the blood-brain barrier,
attack them in the brain [165,166]. Some viruses, including
influenza, do contain genetic sequences that mimic human myelin
Figure 5. mRNA expression heatmap for the PP/SP signature. SPMS samples (yellow), PPMS (grey).
doi:10.1371/journal.pone.0014176.g005
MS Transcription Factor Map
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linked exacerbation of MS lesions to viral infection [167–171];
however, the studies usually target the relapsing forms of the
disease rather than the primary progressive form, which is where
we find the connection to these ribosomal proteins linked to a viral
pathway.
Analysis of Differential Gene Co-Expression
In this section, we report on the results of applying our second
method of differential gene (co-)expression analysis. A kNN-MST
clustering algorithm [172,173] was applied to the detection p-
value prefiltered whole genome mRNA expression data set (19,000
probes) to produce a clustering of nodes. More formally, the
clustering result is a forest, a collection of disjoint graphs such that
each component is a tree (a connected graph with no cycles). Each
cluster corresponds to a particular tree in the forest. Each node
corresponds to an mRNA probe sequence. Nodes are connected to
its nearest neighbour according to a distance metric based on pair-
wise differential co-expression (see Materials and Methods section
for details). A pair of nodes whose expression is perfectly correlated
in control samples and perfectly anti-correlated in MS samples (or
vice versa) has a distance of zero; the distance increases as
expression in controls and MS correlates better. In total, 448
clusters were found, 22 of which contain more than one hundred
Figure 6. mRNA expression heatmap for the PP/RR signature. RRMS samples (red), PPMS (grey).
doi:10.1371/journal.pone.0014176.g006
MS Transcription Factor Map
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is depicted in greater detail in Figure 12 (Figure 11 contents are
provided as a graphics markup language file in supporting
information Figure S1).
Of particular interest are nodes with many immediate
neighbours – a configuration that we call a ‘star’. Each star
contains a designated centre node and its immediate neighbours; a
high cardinality star has a centre with at least twenty neighbours.
A star indicates that a group of genes exhibit differential co-
expression between two different class labelling; in this case to the
control and MS groups only. The co-expression of the centre with
each neighbour (inversely) correlates over one sample group but
not the other. To illustrate, a plot of the correlation behaviour of
one star centre (a probe for INSR, Insulin Receptor) with its
neighbours is shown in Figure 13. In total, there were 39 high
cardinality stars; the members of these stars and their correlation
plots are given in supporting information Table S7 and Figure S2,
respectively.
Profiles containing overrepresented regulatory sequences were
obtained for the 39 high cardinality stars. The members of the
stars were assigned to one of 15 groups according to the cluster
containing the star, which were profiled for overrepresented
TRANSFAC binding motifs using GATHER [95]. Figure 14
shows the complete profiles for the 15 groups. The three most
Figure 7. mRNA expression heatmap for the RR/SP signature. RRMS samples (red), SPMS (yellow).
doi:10.1371/journal.pone.0014176.g007
MS Transcription Factor Map
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(V$SOX5_01), the CREB family (V$CREB_Q4_01), and the
CREB and ATF families (V$CREBATF_Q6), all with similar p-
Value ,6.6E-6. Again, we also obtained higher-level regulatory
sequences (Figure 14, HS column, and Table 1); the two most
significant were for the E2F-1:DP-1 heterodimer (V$E2F1DP1_0)
and the E2F-4:DP-2 heterodimer (V$E2F4DP2_01), with p-
Values ,3.31E-6.
A significantly large proportion of these motifs intersect with
those in the TRANSFAC profiles of the signatures (see Figure 15).
In particular, 80 motifs – or 78.4% of the signature motifs and
41.5% of the star motifs – occur in at least one star profile and one
signature profile (the expected likelihood of this event under
uniform random selection of motifs is less than one in 10
9, i.e. p-
value ,10
29). A similar proportion occurs in the intersection
between the star and up/down regulated signature subset profiles:
75 motifs, or 77.3% of the up/down signature subset motifs and
38.9% of the star motifs (again: p-value ,10
29).
The significant agreement between the two approaches is
notable because patterns of differential expression and differential
co-expression are unlikely to contain a large number of the same
genes. This is indeed the case; there are 790 and 1,256 unique
probes in the signatures and stars respectively, only 53 of these
(6.7% and 4.2% respectively) occur in the intersection. The
agreement in the regulatory motifs between both approaches could
be explained by the occurrence of transcriptional dysregulation in
MS, mediated by the transcription factors associated with these
particular regulatory sequences.
Remarks on the Composition of the set of ‘‘stars’’. We
now highlight some of the probes that correspond to ‘‘stars’’, seem
to indicate genes that are differentially co-expressed in MS
patients.
ASPM (ASP (abnormal spindle) homolog, microcephaly asso-
ciated (Drosophila)) is a centrosome protein [174] which initially
was considered to be a major determinant of cortical size [175],
but its function is now revisited [176–179], however its relatively
recent positive selection status remain unquestioned. ASPM is also
a highly accelerated region that holds key features that make us
human [112], including perhaps language [180–182]. Deficits in
ASPM’s functions has been consistently associated with neurode-
velopmental disorders, primary in microencephaly [183–188].
PTPRN (protein tyrosine phosphatase, receptor type, N),
appears in the literature with different names (IA2, IA-2, IA-2/
PTP, ICA3, ICA512, ICA 512, Islet cell antigen 512, Islet cell
autoantigen 3). The literature reports associations with insulin
dependent diabetes mellitus [189–194] and influences not only the
secretion of hormones but also of neurotransmitters [195], brain
development [196]. Disruption of PTPRN results in alterations in
insulin secretion and glucose tolerance [197].
A probe for INSR, the Insulin Receptor (probe
ILMN_1670918), has lost its pattern of co-expression with a
group of 20 other probes. If the INSR has lost co-expression in MS
Figure 8. TRANSFAC motif profiles for the seven signatures (blue
bars). Only significant motifs (p-value #0.05) are shown. Bar size is
proportional to the negative natural logarithm of p-value, which is also
given as a number. Note that, in contrast to other pairs of profiles, there
is a sizeable intersection between the C/RR and C/SP profiles (green
ring). ‘‘Key’’ regulators of each profile, which are found by hitting set
analysis, are indicated by dots underneath a bar (see figure legend). The
TRANSFAC profile for the set containing all the key regulators’ coding
genes is shown (orange bars); this profile in effect contains ‘‘higher
level’’ regulators – i.e. a hierarchy with a next level of putative
regulators of regulators.
doi:10.1371/journal.pone.0014176.g008
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effects on the insulin signaling pathway. Indeed, MAPK3 also
belongs to the insulin signaling pathway and has also been
identified at the centre of a star with 23 neighbours. It is
noteworthy that GATHER brings Insulin signalling pathway
(KEGG hsa04910, p-Value ,1E-4, Bayes 5) as the most
significant when all neighbours of the 39 stars are searched; 17
out of the 21 probes that appear in the insulin signalling pathway
(including INSR and MAPK3 themselves) have V$KROX_06 as
a binding motif, and all 21 have V$E2F_Q6, pointing again to the
Table 1. Regulators of regulators: binding motifs/transcription factors appearing in the higher level regulation network.
Binding motif Transcription factor HS of In which HS p-value
1. V$E2F1DP1_01 (M00736) E2F-1/DP-1 heterodimer HS-Clust 3-hs 3.31E-06
2. V$E2F4DP2_01 (M00739) E2F-4/DP-2 heterodimer HS-Clust 1-, 3-hs 3.31E-06
3. V$DEAF1_01 (M01001) DEAF1 HS-Sig 2-, 3-hs 4.28E-05
4. V$CREB_Q2_01 (M00916) CREB HS-Clust 1-, 2-, 3-hs 6.57E-05
5. V$E2F1_Q6_01 (M00940) E2F-1 HS-Clust 2-hs 7.87E-05
6. V$KROX_Q6 (M00982) KROX/EGR family HS-Clust 1-, 3-hs 2.03E-04
7. V$CREB_Q4_01 (M00917) CREB family HS-Clust 3-hs 7.25E-04
8. V$HNF3B_01 (M00131) HNF3beta HS-Clust 2-, 3-hs 7.62E-04
9. V$E2F1_Q6 (M00431) E2F-1 HS-Sig 1-, 2-, 3-hs 1.76E-03
10. V$CREB_Q2_01 (M00916) CREB HS-Sig 2-, 3-hs 2.09E-03
11. V$CREL_01 (M00053) c-Rel HS-Sig 1-, 2-, 3-hs 2.48E-03
12. V$ZTA_Q2 (M00711) Zta HS-Clust 1-, 2-, 3-hs 3.21E-03
13. V$ICSBP_Q6 (M00699) ICSBP HS-Sig 2-, 3-hs 4.99E-03
14. V$ELK1_02 (M00025) ELK1 HS-Sig 3-hs 7.45E-03
15. V$MAZ_Q6 (M00649) MAZ HS-Clust 2-, 3-hs 8.92E-03
16. V$E2F_Q6 (M00427) E2F HS-Clust 3-hs 1.41E-02
HS of identifies the origin of the binding motif: ‘HS-Clust’ indicates the hitting set of hitting sets of star cluster profiles, ‘HS-Sig’ indicates the hitting set of hitting sets of
signature profiles (see Figure 11 and Figure 9). In which HS identifies in which of the (1-, 2- or 3-) hitting sets does the binding motif appear.
doi:10.1371/journal.pone.0014176.t001
Figure 9. The A) up- and B) down-regulated signature subsets. (Note that when two groups were combined, the genes in the intersection are
also included in the analysis). The most significant transcription factor motifs associated with a group are shown in square brackets.
doi:10.1371/journal.pone.0014176.g009
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signalling regulation.
The star corresponding to UniGene HS.495215 (T-cell antigen
receptor alpha (TCRA), probe ILMN_1820392) has 56 neigh-
bours. Of these 56, 15 have also appeared in one of our seven
genetic signatures. With the exception of only one, they have
appeared in either the signatures C/PP or C/RR. There is a
relative big number of ribosomal proteins associated (RPL24,
RPL27, RPL35, RPS10, RPS14, RPS17 (Ribosomal proteins L24,
L27, L35, S10, S14, S25, S17), LOC441246 (ribosomal protein
L35 pseudogene 5), LOC285900 (ribosomal protein L6 pseudo-
gene 20), LOC646483 (ribosomal protein L6 pseudogene 19). We
have also found CD3D (CD3d molecule, delta (CD3-TCR
complex)), GNL3/Nucleostemin (guanine nucleotide binding
protein-like 3 (nucleolar)) SNRPD2 (small nuclear ribonucleopro-
tein D2 polypeptide 16.5 kDa), SEC11A/Endopeptidase SP18
(SEC11 homolog A (S. cerevisiae)), TOMM7 (translocase of outer
mitochondrial membrane 7 homolog (yeast)). The only downreg-
ulated gene (in a signature SP/PP) is MAD2L1BP (MAD2L1
binding protein). From this group, it is perhaps CD3D and its the
relationship with the TCRA locus that caught our immediate
attention, since progress in the understanding of CD3D’s functions
come from studies on its deficiency, defects and/or inactivation
[160,198–204]. CD3D is a receptor involved in TCR activation
[158] which has been recently found to be a biomarker for chronic
graft-versus-host disease in mononuclear cell samples from
allogeneic hematopoietic stem cell transplantation recipients
[205] and primary Sjo ¨gren’s syndrome [206]. CD3D promotes
the progression of early thymocytes towards the double positive-
stage [160,207,208]. GNL3/Nucleostemin, is a gene implicated in
cell cycle/growth/progression [209,210], neural progenitor activ-
ity [211], which has also been linked to bipolar disorder [212].
However, upregulation of GNL3 may also lead to apoptosis [213].
Interestingly, of the genes present in the MS signature only
three, two of which are ribosomal proteins, occur in any of the 39
highest cardinality stars (all three are neighbours rather than star
centres). Of the 790 genes differentially expressed in some
signature, three are also star centres (PTPRN, underexpressed in
C/RR; C20orf134, an uncharacterized protein overexpressed in
C/PP, and Hs.443993, another uncharacterized transcribed locus
overexpressed in PP/SP), while fifty appear as neighbours of star
centres. Of these 53 genes, sixteen (30%) appear in a single star,
the star with centre Hs.495215 (T-cell antigen receptor alpha
locus, TRAV38-1), most of which come from C/PP and C/RR.
The TRAV38-1 star is strongly associated with ribosomal proteins.
Discussion
Inthis paper we have analysed gene expression datawith a variety
of computational methods with the aim of uncovering transcription
factors that potentially dysregulate in MS or one or more of its
disease subtypes. Table 1, Table 2 and Table 3 summarise the most
significant transcription factors uncovered by our methods. Of these,
the most significant are KROX/EGR family members, ATF2, YY1
(Yin and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodimers,
SOX5, DEAF1, and CREB and ATF families.
The YY1 transcription factor (Yin and Yang 1)
The zinc finger protein YY1 [214] can be a transcriptional
activator or repressor of several genes (including those for ribosomal
Figure 10. TRANSFAC motif profiles for the up- (red bars) and
down- (green bars) regulated signature subsets. Profiles for
subset unions are also shown; for instance C/PP+C/RR contains the up
(red) or down (green) regulated genes from the union of the C/PP and
C/RR signatures (Figure 8 depicts all the signature subsets and subset
unions.) The bottom row (blue bars) is the profile for all genes in the C/
PP, C/RR and C/SP signatures. Size of bar is proportional to the negative
natural logarithm of p-value, which is also given as a number. Only
significant motifs (p-value #0.05) are shown.
doi:10.1371/journal.pone.0014176.g010
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known roles in replication, cell proliferation, differentiation, and
developmental processes [214,217–220]. It also regulates T-cell
cytokine gene expression [221] and the immune response [222,223]
and its relationships with viral replicating processes [224].
Experiments in mice seem to indicate that the T-cell specific
expression of CD3delta is regulated, in part, by YY1 which
represses the promoter activity strongly in non-T cells [225]. The
disruption of Epstein-Barr virus latency in B cells is induced by
expression of BZLF1 immediate-early protein, and this transcrip-
tionis negatively regulated byYY1 [226,227]. A motif for inhibitory
activity of YY1 on the PrP gene has been observed. The multiple
functions of the YY1 transcription factor in the nervous system have
been recently reviewed [226,228], and enhanced transcription of
the proteolipid protein (PLP), one of the most abundantly expressed
myelin proteins, has also been observed [229].
YY1 inhibits human papillomavirus (HPV) replication in vitro,
and binds the human papillomavirus-6 E1 promoter [230]. It has
been suggested as a negative regulator in the differentiation-
induced HPV-6 E1 promoter and the HPV life cycle (see also the
link between YY1 and the long control region of HPV-16, as
reported in [231]). Nearly half of the intermediate and late gene
transcriptional promoters of vaccinia virus have a binding site for
the YY1 transcription factor that overlaps the initiator elements,
acting as a negative regulator [232]. It also seems to be implicated,
together with SP1 and SP3, on the establishment or reactivation of
varicella-zoster virus latency [233]. The non-structural protein NS
of the Rift Valley fever virus interacts with the host protein SAP30
and with YY1, and as a consequence antagonize interferon-beta
gene expression [234]. The Hepatitis C virus core interacts with
the C-terminal end of the nucleolar phosphoprotein B23, and the
recruitment of p300 reducing the repression effect of YY1 [235].
Table 2. The most significantly overrepresented TRANSFAC motifs found in this study.
Binding motif Transcription Factor Profile p-value
Via profiling the signatures
1. V$CREBP1CJUN_01 (M00041) ATF2/c-Jun heterodimer C/SP 1.38E-4
2. V$ATF_B (M00338) ATF family C/SP 1.92E-4
3. V$TEL2_Q6 (M00678) TEL2 C/PP 2.41E-4
4. V$CREB_Q2 (M00177) CREB C/RR 6.49E-4
5. V$VMYB_01 (M00003) V-MYB C/PP 8.01E-4
6. V$ELK1_02 (M00025) ELK1 C/RR 8.67E-4
7. V$CETS1P54_01 (M00032) ETS1 RR/SP 8.67E-4
8. V$CREBP1_Q2 (M00179) ATF2 C/SP 1.14E-3
9. V$ATF_B (M00338) ATF family C/RR 1.63E-3
10. V$NFKAPPAB65_01 (M00052) NF-KappaBeta (p65) C/RR 1.95E-3
Via profiling the up/down regulated signature subsets
1. V$KROX_Q6 (M00982) KROX/EGR family C/PP+C/RR (-) 3.31E-6
2. V$KROX_Q6 (M00982) KROX/EGR family C/PP+C/RR+C/SP (-) 6.59E-6
3. V$CREBP1_Q2 (M00179) ATF2 C/PP+C/RR+C/SP (+) 9.93E-6
4. V$CREBP1_Q2 (M00179) ATF2 C/RR+C/SP (+) 1.65E-5
5. V$CREBP1_Q2 (M00179) ATF2 C/SP (+) 1.65E-5
6. V$YY1_02 (M00069) YY1 C/PP+C/RR+C/SP (+) 1.65E-5
7. V$CREBP1CJUN_01 (M00041) ATF2/c-Jun heterodimer C/SP (+) 3.30E-5
8. V$YY1_02 (M00069) YY1 C/PP+C/RR (+) 4.28E-5
9. V$CREBP1CJUN_01 (M00041) ATF2/c-Jun heterodimer C/RR+C/SP (+) 1.19E-4
10. V$YY1_02 (M00069) YY1 C/PP+C/SP (+) 1.22E-4
Via profiling the star groups
1. V$SOX5_01 (M00042) SOX5 final_1 6.59E-6
2. V$CREB_Q4_01 (M00917) CREB family final_2 6.59E-6
3. V$CREBATF_Q6 (M00981) CREB and ATF families final_1 9.93E-6
4. V$HTF_01 (M00538) final_12 1.65E-5
5. V$E2F_Q4 (M00426) E2F/DP heterodimers final_2 2.65E-5
6. V$E2F1_Q6_01 (M00940) E2F-1 final_2 2.65E-5
7. V$NRF2_01 (M00108) NFE2L2 (NRF2) final_10 2.65E-5
8. V$CREB_Q2_01 (M00916) CREB family final_1 3.30E-5
9. V$MINI20_B (M00324) final_1 3.30E-5
10. V$CREB_Q4_01 (M00917) CREB family final_1 6.57E-5
In the Profile column, (+)a n d( 2) indicate up- and down-regulated subsets respectively. The ‘+’ in names like C/PP+C/RR (2) indicates the union of the named
signatures.
doi:10.1371/journal.pone.0014176.t002
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ment [236]. The perturbed expression of YY1 in the development
of acute myeloid leukemia has been also highlighted by Erkeland
et al. who observed that these gene tends to harbour viral
integrations of the 1.4 strain of Graffi murine leukemia virus [237].
The role of overexpression of YY1 in the differentiation of
oligodendrocyte progenitors has been studied in [238], conditional
ablation of YY1 in the oligodencrocyte linage gives phenotypes
which have defective myelination, ataxia and tremor. YY1 is then
seen as a repressor of the transcriptional inhibitors of myelin gene
expression (Tcf4 and Id4), by a mechanism that includes the
recruitment of HDAC1 to their promoters during oligodendrocyte
differentiation [239].
In summary, YY1 transcription factor seems to be playing a key
role in the pathogenesis of MS or its subtypes, given its connection
to processes affecting myelin protein generation, viral replication
and immune response processes. It appears as one the most
significant transcription factors related to the differential expres-
sion of genes in MS patients.
The EGR/KROX family
A motif for the Early Growth Response family (KROX/EGR
family motif, V$KROX_Q6) was one of the most significantly
overrepresented motifs identified by this study. A member of this
family, EGR2/KROX-20 has been previously associated with the
regulation of Schwann cells [240] (which in turn are known to be
Figure 11. The seventeen largest clusters. The clustering results from using a distance measure based on changes in correlation of gene
expression between classes.
doi:10.1371/journal.pone.0014176.g011
MS Transcription Factor Map
PLoS ONE | www.plosone.org 15 December 2010 | Volume 5 | Issue 12 | e14176Figure 12. The largest cluster from Figure 11 with a different layout. Nodes represent probes, colour and size indicate its centrality in the
graph (number of connected nodes). Some of the prominent ‘‘stars’’ have been labelled.
doi:10.1371/journal.pone.0014176.g012
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[242,243]). In Schwann cells, progesterone has also been shown
to stimulate KROX-20 expression [244–249].
Activation of KROX-20 is an indispensable transcription factor
for myelination and a prerequisite for Schwann cell differentia-
tion’’ [250]. EGR1 and EGR3 (we have already observed the later
as upregulated in PPMS in comparison to Controls) provide a
balance to EGR2/KROX-20 in Schwann cells. It has been
hypothesised that the pair should be expressed prior to start
myelination, be downregulated on myelination, but be again
upregulated as Schwann cells dedifferentiate after injury [136] (see
also [251–253]). There exists an antagonist effect of EGR1 and
EGR2 in Schwann cells [254]. EGR1 has been previously found
disregulated in a genome-wide expression profiling analysis of
synchronously differentiating olygodendrocytes generated from
pure precursor cells in vitro, and comparing with the program of
cells in vivo. In that study, a probe for EGR1 was found to be the
most strongly expressed specifically in undifferentiated oligoden-
drocyte precursor cells [255]. A possible joint dysregulation of
members of this family could be explored to see if they have a role
in the differentiation of oligodendrocytes [256,257].
As it was the case of the YY1 transcription factor, this family role
in the immune response has to be monitored as there are reports of
EGR/KROX being negative regulators of T cell activation [131],
having roles in T cell anergy [133,258–261], upregulation of Fas
ligand [262] and TNF [263], CD154/CD40 ligand on CD4 T cells
[264], autoreactive T cell activation [265], upregulation of cell cycle
inhibitors p21(cip1) and p27(kip) (as studied in tolerant T cells
following antigen challenge in vivo), interact with NF-kappaB p50
and p65 [266], regulate proinflammatory cytokines [267], as well as
thymocyte development [268,269].
ATF2 and SOX5
Studies of homozygous shiverer mutant mice have identified
ATF2 as a regulator of the expression of MAG expression at a
specific stage of shi/she oligodendrocyte differentiation [270]. It
Figure 13. Correlation plot for the insulin receptor star centre (INSR). The figure shows the correlation of scaled expression values of INSR
(insulin receptor, purple line) with the average of negatively (left column) and positively (right column) correlated neighbour probes (coloured dots).
The light blue vertical line separates control samples to the left and MS to the right. The figures show three different orderings: by the harmonic
mean of neighbours (top row), by the star centre expression value (middle row) and by the difference between star centre and neighbours average
(bottom row). The class correlation values of star centre with neighbours are shown in the top figure; for example, r(2,C) is correlation coefficient of
negatively correlated probes with control samples and r(+,MS) is the correlation of positively correlated probes with MS samples. Dot colours indicate
sample class: green – control, blue – PPMS, red – RRMS, yellow – SPMS. This graph illustrate patterns of differential co-expression in Control versus MS
samples. In particular, on the left it can be observed that some neighbours are strongly anti-correlated with the star centre in controls (correlation
coefficient 20.744) but weakly correlated in MS (0.130); on the right, the remaining neighbours are strongly correlated with the centre in controls
(0.739) but weakly anti-correlated in MS (20.233).
doi:10.1371/journal.pone.0014176.g013
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murine encephalomyelitis virus induces a type of demyelination in
mice that that that resembles human MS, and also observed
induction of ATF2 30 minutes after the infection of macrophages
[271]. A study of a mycobacterial antigen suggests that ATF-2
might control expression of CREB and c-Jun during T cell
activation and that of expression of IFN-gamma [272].
Another transcription factor motif significantly overrepresented
is SOX5 (p-value ,6.59E-6). Together with SOX6, SOX5 was
identified as cell-autonomously regulating several stages of
oligodendrocyte development in the mouse spinal cord (via
repression of specification and terminal differentiation and
influence migration patterns) [273].
KROX/EGR Family and YY1 are Further Indicated by
Involvement in T Cell Specification
It is widely believed that T cells are central to the pathogenesis of
MS; autoreactive T cells are hypothesised to coordinate an attack
against central nervous system myelin, triggering an inflammatory
response leading to neurological damage. However, the origin of the
autoreactive lymphocytes is unknown. We looked for a correspon-
dencebetweentheregulatorsthatwefoundaboveandthoseofTcell
specification (the process by which haematopoietic stem cells
progress through intermediate progenitor cell types to mature T
cells), whichmay help toidentify a defectinthe T celldevelopmental
program in MS. Such defects have been linked to many diseases,
including a proposed contribution to diabetes susceptibility in non-
obese diabetic mice, with CD4+CD8+ blasts that have abnormally
high expression of IL-7Ralpha, and c-Kit [274].
Cell specification is well understood for T cells compared to
most other cell types and many regulators of the process have been
identified. In two recent comprehensive studies, a sizeable network
of regulatory relationships involved in T cell specification was
constructed [275] and the expression of more than 100 regulatory
genes characterized in early T cell progenitors [276]. Table 3 lists
the transcription factors that are known to participate in T cell
specification [275,276] and which are indicated by our above
analyses of differential expression as potentially playing a role in
Figure 15. Number of motifs found in common between the
different analytical approaches. Number of motifs occurring in the
A. signature profiles, B. up/down regulated signature subset profiles,
and C. cluster profiles.
doi:10.1371/journal.pone.0014176.g015
Figure 14. TRANSFAC motif profiles for the fifteen clusters
found by correlation clustering (cyan bars). Only ‘‘key’’ regulators
of each profile,whicharefoundbyhitting setanalysis (see figure legend),
are shown. The TRANSFAC profile for the set containing all the key
regulators’ coding genes is shown (orange bars); this profile in effect
contains ‘‘higher level’’ regulators – regulators of regulators. Size of bar is
proportional to the negative natural logarithm of p-value, which is also
given as a number. Only significant motifs (p-value #0.05) are shown.
doi:10.1371/journal.pone.0014176.g014
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EGR family and the Yin and Yang 1 transcription factor, which
are both indicated in several different signatures and clusters.
YY1, IKAROS and other ‘‘legacy transcription factors’’ are
relatively unchanged during early T-lymphocyte
specification and commitment
T-cell lineage differentiation is an ongoing process in mammals
with a clear transcription factor ‘‘armature’’ regulation [277] that
is currently being thoroughly mapped [275,278,279]. Defects on
the T-cell developmental program have been linked to many
diseases, including a proposed contribution to diabetes suscepti-
bility in non-obese diabetic mice, with CD4+CD8+ blasts that
have abnormally high expression of IL-7Ralpha, and c-Kit [274].
To obtain a time-series of early T-cell development for gene
expression analysis, David-Fung et al. sorted subsets of immature
mouse thymocytes from postnatal, weanling mice. Stages of
development were based on the expression of CD44, CD25, and
the growth factor receptor c-Kit and markers CD44, CD25 and
the heat-stable antigen (CD24) and CD27. In the first stages of T-
cell development the cells that enter the thymus are defined as
‘‘double negative’’ (DN), since they do not have the T-cell markers
of maturity (CD4 and CD8). David-Fung et al, indexed these
stages in terms of increasing maturity as DN1 (or early T-cell
precursor, ETP), DN2, DN3a, DN3b, and DN4. Using four
independent series of samples (from normal, young adult mice),
DN1, DN2, total DN3, and DN4 cells were collected in each of
the first two sets (‘‘sets 1 and 2’’, Series A). In the second two sets
(‘‘sets 4 and 5’’, Series B) the DN3 cells were subdivided into
DN3a (pre-selection) and DN3b (the first stage past b-selection).
YY1, together with Ikaros (Ikzf1), MYB and other transcription
factors have been shown to have minimal changes from DN1 to
DN3 stage. The list of other transcription factors that have critical
roles in T-cell differentiation and development, and that have
minimal changes of gene expression also includes MLL1, Gfi-1,
GABPa, Stat5b, Oct1 (Pou2f1), and TOX. More recently, David-
Fung et al have included YY1 together with FOG-1 (Zfpm1),
Gse1, and Zfp598 to this list of ‘‘legacy genes’’ [276]. This is in
sharp contrast with other genes that have large changes in T-
lineage gene expression. Examples include Aiolos (Ikzf3), Gata3
[280,281], and others that have clear patterns of upregulation
during DN1 to DN3 progression (for the complete list see [276]).
A Hypothetical Network of Transcription Factors that
Dysregulate genes in MS
If transcription factors do dysregulate genes in MS, it is reason-
able to suspect that some are only associated with specific disease
subtypes. Based on our data, we propose the following speculative,
Table 3. The 25 most significantly overrepresented binding motifs/transcription factors that have coding genes involved in T cell
specification.
Binding motif Transcription factor Profile Gene(s) p-value
1. V$KROX_Q6 (M00982) EGR family C/P+C/R(2) EGR1, EGR2, EGR3 3.31E-06
2. V$YY1_02 (M00069) YY1 C/P+C/R(+) YY1 1.65E-05
3. V$KROX_Q6 (M00982) EGR family C/R(2) EGR1, EGR2, EGR3 6.25E-05
4. V$KROX_Q6 (M00982) EGR family HS EGR1, EGR2, EGR3 2.03E-04
5. V$YY1_02 (M00069) YY1 C/P(+) YY1 2.41E-04
6. V$KROX_Q6 (M00982) EGR family C/R+C/S(2) EGR1, EGR2, EGR3 4.62E-04
7. V$ER_Q6 (M00191) ER All genes ESR1 4.62E-04
8. V$CETS1P54_01 (M00032) C-ETS-1(P54) RR/SP ETS1 8.67E-04
9. V$E2F_Q3_01 (M00918) E2F All genes TFDP1 1.84E-03
10. V$CDP_01 (M00095) CUTL1 C/P+C/R(2) ETS1 2.09E-03
11. V$YY1_02 (M00069) YY1 C/P+C/S(+) YY1 2.22E-03
12. V$EBF_Q6 (M00977) EBF final_53 EBF 2.48E-03
13. V$ER_Q6 (M00191) ER C/P+C/R(+) ESR1 2.63E-03
14. V$KROX_Q6 (M00982) EGR family final_25 EGR1, EGR2, EGR3 2.74E-03
15. V$ER_Q6 (M00191) ER C/MS ESR1 2.74E-03
16. V$OCT1_Q6 (M00195) OCT1 final_25 POU2F1 3.06E-03
17. V$EBF_Q6 (M00977) EBF final_25 EBF 3.21E-03
18. V$KROX_Q6 (M00982) EGR family HS EGR1, EGR2, EGR3 3.21E-03
19. V$CETS1P54_01 (M00032) C-ETS-1(P54) final_63 ETS1 3.38E-03
20. V$TCF1P_Q6 (M00670) TCF1 final_63 YY1 3.38E-03
21. V$KROX_Q6 (M00982) EGR family C/P(2) EGR1, EGR2, EGR3 3.38E-03
22. V$IK3_01 (M00088) IK-3 PP/SP AIOLOS 4.99E-03
23. V$KROX_Q6 (M00982) EGR family All genes EGR1, EGR2, EGR3 5.92E-03
24. V$E2F_Q3_01 (M00918) E2F C/P+C/R(2) TFDP1 5.92E-03
25. V$ER_Q6 (M00191) ER C/S(2) ESR1 6.22E-03
Profile identifies the TRANSFAC profile (‘HS’ is the hitting set profile for the signatures, see Figure 9; ‘All genes’ is the profile for the union of all genes in the C/PP, C/RR,
C/SP signatures. Gene(s) gives the corresponding T cell specification regulatory genes identified in [275,276].
doi:10.1371/journal.pone.0014176.t003
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subtype. The model is limited to transcription factors currently
known to be involved in T cell specification [275]. It is informally
constructed with the transcription factors indicated by the
TRANSFAC analysis of the signatures (see Figure 9), which
distinguish between disease subgroups or between controls and
disease subgroups.
The model is illustrated in Figure 16. Each node in the model
lists transcription factors that dysregulate in one of the node’s
outcomes. Under the model, dysregulation by CREB/ATF, E2F
families, ELK-1, MAZR and principally by KROX, V-MYB and
YY1 characterises MS overall. Dysregulation by CHOP, COUP-
TF, HNF4 heterodimer, DEC, FOXD3, GATA-1, PAX9-B, SRF
and TEL-2 characterises PPMS. CCAAT box, E2F-1/DP-1 and
E2F-4/DP-2 heterodimers, NF-kappaB (p65), TTF-1 and Zta
characterises RRMS. Finally, ATF-1, HNF-4alpha1 and NF-Y are
the transcription factors associated with SPMS. Lack of evidence
of dysregulation by the afore mentioned groups, but dysregulation
by CDX-2, E2, E47, MyoD and SP3 might indicate that exclusion
from MS cannot be asserted. Note that under this model SPMS
has the least characteristic group of transcription factors, and there
is some overlap with MS as a whole.
Figure 16. Speculative initial sketch for a model of transcription factors currently known to be involved in T cell specification and
which may also be involved in the pathogenesis of MS, showing links to disease subtype. Other transcription factors that also need to be
added to this model are those which we have found very relevant in our analysis such as the Early Growth response EGR/KROX family, ATF2, YY1 (Yin
and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodimers, SOX5, and CREB and ATF families.
doi:10.1371/journal.pone.0014176.g016
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research for identifying transcription factors involved in the
pathogenesis of MS, as it relies on simplifying and biologically
naı ¨ve assumptions – for instance, T cell specification does not
occur in peripheral blood, where the samples were collected, but in
the thymus, but effects on peripheral blood are still measurable.
Thus, there is room for refinement and it could be extended also
by considering other transcription factors such as the key
regulators identified by the hitting set analyses. However, our
hope is that this model can be used to corroborate other findings,
single out transcription factors for more detailed research, and
participate in unravelling some of the heterogeneity in MS.
Conclusions
Using state-of-the-art bioinformatics methods, our analysis
uncovered a network of transcription factors that putatively
contribute to the dysregulation of several genes in MS or one or
more of its disease subtypes. Separate analytical methods were
used on the same dataset, involving sophisticated mathematical
algorithms to solve combinatorial optimization problems. We
noted a convergence of findings, leading to a set of transcription
factors which are involved in the early T-lymphocyte specification
and commitment as well as in oligodendrocyte dedifferentiation
and development. The most significant transcription factors motifs
were for the Early Growth response EGR/KROX family, ATF2,
YY1 (Yin and Yang 1), E2F-1/DP-1 and E2F-4/DP-2 heterodi-
mers, SOX5, and CREB and ATF families.
Materials and Methods
Ethics Statement
Institutional Human Research Ethics Committees approval to
conduct this study was obtained by the Chief Investigators of the
ANZgene Consortium, that included: E08/910 from Eastern
Health Research and Ethics Committee (VIC), Research Appli-
cation 105/07 from Flinders Medical Centre Research Ethics
Committee (SA), GU Protocol HSC/09/03/HREC from Griffith
University (QLD), MEC/07/12/176 from Multi-Region Ethics
Committee (NZ), 05/04/13/3.09 from Hunter New England
Human Research Ethics Committee (NSW), H-505-0607 from the
University of Newcastle Human Research Ethics Comitee (NSW),
HREC #1980 from The University of Sydney Human Research
Ethics Committee (NSW) and H0009782 from the Human
Research Ethics Committee (Tasmania) Network (TAS).
Written informed consent was obtained from all subjects prior
to participation in this project.
Patients, Phenotyping, and Inclusion Criteria
A cohort of 99 people with MS and 45 healthy controls was
recruited from Sydney, Newcastle (NSW) and Gold Coast (QLD).
Diagnosis of MS was confirmed using the revised McDonald
criteria [282]. Further separation into RRMS, SPMS and PPMS
cases was done according to published criteria [283,284]. Patient
demographics are given in Table 4. All patients had no
immunomodulatory therapy for at least three months prior to
sample collection.
RNA Extraction, Microarray Protocols
The peripheral blood samples were collected between 9AM and
1PM and total RNA was extracted from the whole blood in
PAXgene tubes using PAXgene
TM Blood RNA kit (Qiagen,
Germany) according to the manufacturer’s instruction unless
otherwise stated. Total RNA quality was assessed and its
concentration was measured using Agilent RNA 6000 series II
Nano kit (Agilent Technologies, CA, USA). Minimum RNA
Integrity Number (RIN) of .7 was employed for each sample to
pass the quality assessment. 250 ng total RNA from each sample
was biotinylated and amplified using IlluminaH TotalPrep RNA
Amplification Kit (Ambion, TX, USA). Total RNA was reverse
transcribed to synthesize first strand of cDNA followed by second
strand synthesis. Double stranded cDNA was then transcribed and
amplified in vitro to synthesize biotin labelled complementary
mRNA (cRNA). The cRNA yield was measured at 260 nm using
NanoDrop 1000A Spectrophotometer. 750 ng of cRNA sample
was hybridized on a human HT-12 expression beadchip (Illumina
Inc., CA, USA) profiling 48,804 transcripts per sample. The chips
were stained with streptavidin-Cye3 conjugate and scanned using
an Illumina BeadArray Reader (Illumina Inc.).
The dataset is available in Gene Expression Omnibus under the
reference GSE17048.
Normalisation and Initial Pre-Filtering
The average signal intensity for each gene was measured using
Beadstudio v3. The sample signals were normalized with cubic
spline in order to minimize variation due to non-biological factors.
Approximately 19,000 genes were selected for differential
expression analysis with detection p-value ,0.01 for at least one
of all samples. The detection p-value measures the probability of
observing signal without specific probe-target hybridization.
Analysis of Differential Expression
A genetic ‘signature’ was obtained from the detection p-value
filtered dataset for each pair of sample groups by applying an
additional two-step filtering process, which removed probes
lacking sufficient discriminative power according to information
content and predictive ability respectively.
1. An entropy-based selection procedure employing Fayyad and
Irani’s multi-class, multi-interval discretisation algorithm [88]
was applied. For each probe sequence, the algorithm finds the
threshold that minimizes the class-information entropy of the
samples, which discretises the dataset (greater than threshold –
1; less – 0). It then discards the genes that do not sufficiently
discriminate between the sample groups according to the
minimum description length principle.
2. Following, an (a,b) k-feature set selection method [89,90] was
applied. The (a,b) k-feature set problem asks, in this context,
for the smallest subset of probe sequences containing: i) at least
a probes differentially expressed (after discretisation) between
every pair of samples in the Cartesian product of the two
sample groups (a probe is differentially expressed between a
pair if their values are 0 and 1), and ii) at least b probes with
Table 4. Demographics of patient and control cohorts.
Sample N M:F Age
Age at
diagnosis Duration EDSS
Controls 45 16:29 48.5 (23–77) – – –
MS 99 33:66 54 (28–97) 35.5 (16–59) 16.5 (1–54) 4.5 (0–9)
PPMS 43 21:22 55.3 (30–87) 42 (21–58) 13 (5–31) 5.6 (2–8)
RRMS 36 7:29 48.5 (29–65) 33 (19–56) 15 (1–36) 2.7 (0–6.5)
SPMS 20 5:15 57.5 (34–73) 35.5 (16–59) 22 (2–54) 6.5 (4–9)
M:F male:female; Age, Age at Diagnosis: Mean and range; EDSS (expanded
disability scale): mean and range.
doi:10.1371/journal.pone.0014176.t004
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of the sample groups. Intuitively, a and b specify the degree of
inter-class differentiation and intra-class similarity respectively.
In practise, we use a maximum and b maximal to facilitate
computation of a solution; Table 5 gives the (a,b) values (and
various summary statistics) for each signature. We refer the
reader to [89,91–93] for mathematical details and applications
of the approach.
Analysis of Differential Co-expression
A cluster map was constructed for the approximately 19,000
probe sequences found to be expressed in whole blood, using a
kNN-MST graph clustering analysis [172,173]. The map connects
each probe to its nearest neighbour under the distance metric
dij~lij 2{ C
(1)
ij {C
2 ðÞ
ij
     
     
  
,
where dij is the distance between probes i and j, Cij
(k) M [-1,1] is the
correlation between i and j in class k (class 1 is controls and class 2
is MS, all subtypes), and
lij~ 2{ C
1 ðÞ
ij
     
     
  
:
Correlation values are computed as a normalized sum of the
Pearson and Spearman correlation coefficients, which is robust
against outliers. The minimum distance between a pair of probe
sequences is dij=0, which occurs when the expression of i and j are
perfectly correlated over controls and perfectly anti-correlated
over disease (or vice versa). A distance of dij=1, which is relatively
short, occurs between a pair of probe sequences correlated (or
anti-correlated) over controls and uncorrelated over disease.
With this definition of distance, high cardinality stars are
particularly important since all (or almost all) the immediate
neighbours of the centre have changed or lost correlation with the centre
in disease. Under our working hypothesis, this effect is attributed to
dysregulation of the transcription factor(s) associated with the
centre and not with the neighbours.
Hitting Set Filter
Our hitting set filter is formally defined as follows. Consider a
set S (of TRANSFAC motifs), a collection C of n subsets C1,…,Cn
# S, and a positive integer m. The elements of S have positive
weights ws (p-values), ms M S. We seek a subset HS # S such that
|HS > Ci| $ m, i = 1,…,n, and Ss ws is minimal. Such a set HS,i f
it exists, is a weight-minimal hitting set because it ‘hits’ all subsets Ci
at least m times.
To illustrate, consider the hitting set instance given in the matrix
shown in Table 6 (left). Each subset Ci is defined by Ci ={ sj | M(i,
j) = ‘x’ }, where M(i,j) is the i,jth entry in the matrix with the row
for w removed; for example, C3 ={ s1, s3, s5}.
On the right, weight minimal solutions are shown for m =
1,…,4. Note that there is a two-fold effect as m grows: first, |HS|
tends to increase with m; but second, beyond a certain point no
satisfying HS exists. Throughout this paper, m = 1, 2, and 3.
We employed CPLEX, an integer linear programming tool, to
efficiently compute solutions to the hitting set instances. The
hitting set problem can be formulated as an integer linear
programming problem as follows
minimise
P
s[S
wsxs
such that
P
s[Ci
xs§mi ~1,...,n,
where xs =1i fs M HS, xs = 0 otherwise.
Supporting Information
Table S1 Signature Control - MS. Heatmap and annotation for
the C/MS signature. Probe Ids, expression values, hitting set
annotation, and gene annotations are given.
Found at: doi:10.1371/journal.pone.0014176.s001 (1.08 MB XLS)
Table 5. Summary of (a,b) k-feature set selection results for each signature.
0-Centered 1-Centered
#0 #1 # EntF Nalfa Amax #ABK Nbeta Bmax Bmxml Nbeta Bmax Bmxml
C/MS 45 99 369 4455 40 145 990 232 79 4851 107 58
C/PP 45 43 360 1935 66 221 990 209 113 903 170 113
C/RR 45 36 366 1620 73 260 990 235 154 630 160 131
C/SP 45 20 317 900 40 113 990 245 67 190 124 67
PP/SP 43 20 133 860 23 77 903 90 48 190 83 53
RR/PP 36 43 126 1548 25 86 630 82 55 903 75 49
RR/SP 36 20 113 720 24 66 630 66 32 190 80 48
#0, #1 are the number of samples in class 0 and class 1 (for example, in the C/MS signature, class 0, Controls, has 45 samples and class 1, MS, has 99 samples). #EntF
is the number of features (probes) satisfying the entropy filtering criterion. Nalfa is the number of alpha pairs. A-max is the maximum number of features for all alpha-
pairs. #ABK is the size of the optimum solution (signature size). Nbeta is the number of beta pairs, considering only one class. B-max is the maximum number of
features for all beta-pairs. Bmxml is the maximum number of features per beta-pair before the solution increases in size. 0-Centered/1-Centered refers to the search
for in-class coherency for class 0 and class 1 respectively.
doi:10.1371/journal.pone.0014176.t005
Table 6. Hitting Set Example.
S
s1 s2 s3 s6 s5 mH S
ws 566781s1
CC 1 xxxxx2s1, s5
C2 xx xx3s1, s2, s3, s5
C3 x x x 4 No solution
doi:10.1371/journal.pone.0014176.t006
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each signature, the probe Ids, expression values, heatmap, hitting
set annotation, and gene annotations are given.
Found at: doi:10.1371/journal.pone.0014176.s002 (1.88 MBXLS)
Table S3 Signatures Control - PPMS, PPMS - SPMS, RRMS -
PPMS and RRMS - SPMS. For each signature, the probe Ids,
expression values, heatmap, hitting set annotation, and gene
annotations are given.
Found at: doi:10.1371/journal.pone.0014176.s003 (2.27 MBXLS)
Table S4 (a,b) k-feature set summary statistics. Summary
statistics of the (a,b) k-feature set selection process for each of
the signatures and combined listing of all signatures, showing over
or under expression and signature overlap. Overlap with the
signatures in the companion study are also given.
Found at: doi:10.1371/journal.pone.0014176.s004 (0.52 MBXLS)
Table S5 TRANSFAC Profiles. Excel file containing the
TRANSFAC profiles for the 7 signatures, 14 up/down-regulated
signature subsets, and 15 star clusters.
Found at: doi:10.1371/journal.pone.0014176.s005 (0.30 MBXLS)
Table S6 g:Profiler functional profiles for signatures. Functional
profiles for each signature. Profiling was performed with
g:PROFILER [163], which integrates several profiling resources,
including Gene Ontology, KEGG and Reactome pathways, and
TRANSFAC sequence motifs. Note that a group of six ribosomal
protein genes (RPL10A, RPL12, RPL39, RPS17, RPS21, and
RPS25P8) are responsible for over half of the significant terms (17
of the 30) in the C/MS profile, and are linked to viral and
translation pathways. Similarly, there is a group of nine ribosomal
genes (RPL27, RPL35, RPL35A, RPL39, RPS5, RPS14,
RPS15A, RPS27A, and RPLP0P2) that are responsible for almost
all the significant Reactome pathway terms in the profile for C/
PP; most of these terms relate to influenza or translation pathways
- principally translation initiation, translation elongation and
influenza viral RNA transcription and replication.
Found at: doi:10.1371/journal.pone.0014176.s006 (0.47 MB PDF)
Table S7 Members of high cardinality stars. Complete member
listing of all 39 high cardinality stars.
Found at: doi:10.1371/journal.pone.0014176.s007 (0.29 MBXLS)
Figure S1 Stars correlation plots. Correlation plots for all high
cardinality stars.
Found at: doi:10.1371/journal.pone.0014176.s008 (8.18 MB PDF)
Figure S2 Largest clusters. The seventeen largest clusters found
by analysis of genes differentially co-expressed over controls and
MS. Figure is in GML format.
Found at: doi:10.1371/journal.pone.0014176.s009 (0.44 MB ZIP)
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